TMCnet News
FDAnews Announces -- FCPA Compliance Roadmap for Drug and Device Companies: Lies, Misconceptions and Traps that Cost Firms Millions Webinar, Oct. 8, 2014(PR Web Via Acquire Media NewsEdge) Falls Church, VA (PRWEB) September 25, 2014 FCPA Compliance Roadmap for Drug and Device Companies: Lies, Misconceptions and Traps that Cost Firms Millions **FDAnews Webinar** Oct. 8, 2014 -- 1:30 p.m. – 3:00 p.m. EDT http://www.fdanews.com/FCPAcompliance Drug and device firms that violate the Foreign Corrupt Practices Act (FCPA) risk untold fines and hassles and even criminal charges. Each year the list of FCPA violators gets longer and the fines go up. In just the last two years, five major drug and device companies have been prosecuted and paid nearly $150 million in fines, disgorgement of profits, penalties and interest. In 90 minutes, top international Washington lawyers Michael Burke and Ed Cadigan of Arnall Golden Gregory LLP reveal lies and misconceptions that can ensnare drug and device firms, leading to noncompliance with FCPA. Attendees will discover: • The 10 misconceptions that may expose a firm to FCPA risk • Recent changes to FCPA enforcement that impact life sciences companies • How to identify FCPA red flags • Supply-chain vulnerabilities • Managing an effective FCPA compliance program • Mitigating FCPA risk in contracts such as distribution agreement • Potential interplay between the FCPA and the UK Bribery Act • And much more! The matter couldn't be more timely. The Justice Dept. says it will step up FCPA enforcement against life sciences companies of all kinds. And Justice and the Securities & Exchange Commission have formed special FCPA Units dedicated to ferreting out FCPA violations across the corporate spectrum. With millions of dollars and years of international legal woes potentially on the line, there's no excuse for not protecting the organization. Meet the Presenters: Michael Burke is a Corporate Practice partner with Arnall Golden Gregory LLP, specializing in FCPA investigations and compliance program development with a focus on U.S. export controls, economic sanctions and anti-boycott regulations. He advises clients on mergers and acquisitions, joint ventures and strategic alliances, private equity, distribution and reseller networks, and technology licensing. Ed Cadagin is an associate in the Litigation and Employment Practice Groups of Arnall Golden Gregory. At Georgetown Law, Mr. Cadagin was chosen to be a Legal Research & Writing Law Fellow and an extern for the Department of Justice, Criminal Division – FCPA Unit. Prior to Arnall Golden Gregory, he practiced employment law with an international Washington DC law firm. Who Will Benefit: • General/corporate counsel • Auditors • Compliance officers • Regulatory professionals • Executive management • Manufacturing directors and supervisors • Sales/marketing personnel • Strategic planning and business development staff • Training personnel • New hires Webinar Details: FCPA Compliance Roadmap for Drug and Device Companies: Lies, Misconceptions and Traps that Cost Firms Millions **FDAnews Webinar** Oct. 8, 2014 -- 1:30 p.m. – 3:00 p.m. EDT http://www.fdanews.com/FCPAcompliance Tuition: $487 per site -- includes webinar registration and audio cds and transcripts Easy Ways to Register: Online: http://www.fdanews.com/FCPAcompliance By phone: 888-838-5578 or 703-538-7600 About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations. Read the full story at http://www.prweb.com/releases/FDAnews/FCPAcompliance/prweb12201681.htm (c) 2014 PRWEB.COM Newswire |